

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/719,695-Conf. #1345
				Filing Date	November 21, 2003
				First Named Inventor	Leong Ng
				Art Unit	1644
				Examiner Name	N. M. Rooney
Sheet	1	of	1	Attorney Docket Number	ISA-01201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Rosen, A. et al., "Autoantigens as Substrates for Apoptotic Proteases: Implications for the Pathogenesis of Systemic Autoimmune Disease," Cell Death and Differentiation, 6:6-12 (1999).	
	CB	Kobayashi, T. et al., "The Increment of Anti-ORP150 Autoantibody in Initial Stages of Atheroma in High-Fat Diet Fed Mice," J. Vet. Med. Sci., 64(2):177-180 (2002).	
	CC	Roma, P. et al., "Stress Proteins and Atherosclerosis," Atherosclerosis, 127:147-154 (1996).	
	CD	Xu, Q. et al., "Serum Soluble Heat Shock Protein 60 Is Elevated in Subjects With Atherosclerosis in a General Population," Circulation, 102:14-20 (2000).	
	CE	Xu, Q. et al., "Association of Serum Antibodies to Heat-Shock Protein 65 With Carotid Atherosclerosis: Clinical Significance Determined in a Follow-Up Study," Circulation, 100:1169-1174 (1999).	

Examiner Signature	/Nora Rooney/	Date Considered	12/04/2009
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.